Veracyte, Inc. (VCYT)
Healthcare • Diagnostics & Research
StockNasdaqGMUnited StatesUS92337F1075
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Veracyte, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:05. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | 0.40 | — | — | Upcoming |
| 04 Nov 2026 16:00 | 0.41 | 0.51 | +24.5% | Beat |
| 30 Jul 2026 16:00 | 0.43 | 0.54 | +25.1% | Beat |
| 05 May 2026 16:00 | 0.33 | 0.52 | +56.0% | Beat |
| 25 Feb 2026 16:00 | 0.41 | 0.53 | +29.8% | Beat |
| 04 Nov 2025 16:00 | 0.32 | 0.51 | +59.5% | Beat |
| 06 Aug 2025 16:00 | 0.30 | 0.44 | +48.5% | Beat |
| 07 May 2025 16:00 | 0.20 | 0.31 | +51.4% | Beat |
| 24 Feb 2025 16:00 | 0.26 | 0.36 | +40.0% | Beat |
| 06 Nov 2024 16:00 | 0.17 | 0.33 | +98.8% | Beat |
| 06 Aug 2024 16:00 | -0.01 | 0.30 | +4,100.0% | Beat |
| 07 May 2024 16:00 | -0.10 | 0.04 | +137.3% | Beat |
| 22 Feb 2024 16:00 | -0.05 | -0.39 | -721.1% | Miss |
| 07 Nov 2023 16:00 | -0.13 | -0.41 | -215.4% | Miss |
| 08 Aug 2023 16:00 | -0.14 | -0.12 | +14.3% | Beat |
| 04 May 2023 16:00 | -0.11 | -0.11 | -1.9% | Miss |
| 22 Feb 2023 16:00 | -0.08 | -0.05 | +34.8% | Beat |
| 02 Nov 2022 16:00 | -0.23 | -0.12 | +48.2% | Beat |
| 02 Aug 2022 16:00 | -0.22 | -0.13 | +40.4% | Beat |
| 03 May 2022 16:00 | -0.23 | -0.20 | +14.6% | Beat |
| 28 Feb 2022 16:00 | -0.15 | -0.14 | +3.9% | Beat |
| 09 Nov 2021 16:00 | -0.14 | -0.20 | -46.3% | Miss |
| 29 Jul 2021 16:00 | -0.25 | -0.13 | +47.1% | Beat |
| 10 May 2021 16:00 | -0.12 | -0.66 | -450.0% | Miss |
| 17 Feb 2021 16:00 | -0.10 | -0.14 | -44.8% | Miss |
| 02 Nov 2020 16:00 | -0.19 | -0.08 | +59.0% | Beat |
| 30 Jul 2020 16:00 | -0.27 | -0.22 | +17.3% | Beat |
| 06 May 2020 16:00 | -0.20 | -0.24 | -22.0% | Miss |
| 25 Feb 2020 16:00 | -0.08 | -0.15 | -83.7% | Miss |
| 22 Oct 2019 16:00 | -0.07 | -0.02 | +70.6% | Beat |
| 30 Jul 2019 16:00 | -0.09 | -0.05 | +42.9% | Beat |
| 30 Apr 2019 16:00 | -0.07 | -0.05 | +31.8% | Beat |
| 25 Feb 2019 16:00 | -0.15 | -0.08 | +45.8% | Beat |
| 29 Oct 2018 16:00 | -0.21 | -0.12 | +41.9% | Beat |
| 23 Jul 2018 16:00 | -0.26 | -0.18 | +32.1% | Beat |
| 01 May 2018 16:00 | -0.25 | -0.27 | -9.1% | Miss |
| 27 Feb 2018 16:00 | -0.20 | -0.24 | -18.5% | Miss |
| 06 Nov 2017 16:00 | -0.21 | -0.21 | +0.9% | In line |
| 31 Jul 2017 16:00 | -0.25 | -0.22 | +11.1% | Beat |
| 03 May 2017 16:00 | -0.23 | -0.24 | -2.1% | Miss |
| 01 Mar 2017 16:00 | -0.26 | -0.14 | +46.2% | Beat |
| 03 Nov 2016 16:00 | -0.21 | -0.20 | +4.8% | Beat |
| 03 Aug 2016 16:00 | -0.33 | -0.40 | -19.7% | Miss |
| 05 May 2016 16:00 | -0.35 | -0.36 | -2.9% | Miss |
| 10 Mar 2016 16:00 | -0.30 | -0.29 | +4.4% | Beat |
| 05 Nov 2015 16:00 | -0.33 | -0.32 | +1.9% | Beat |
| 13 Aug 2015 16:00 | -0.31 | -0.35 | -12.0% | Miss |
| 14 May 2015 16:00 | -0.36 | -0.34 | +4.4% | Beat |
| 19 Mar 2015 16:00 | -0.33 | -0.36 | -9.1% | Miss |
| 13 Nov 2014 16:00 | -0.35 | -0.37 | -6.6% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 517.1M | +16.0% | 66.4M | 12.8% | 0.82 | +164.5% | 126.6M |
| 2024 | 445.8M | +23.5% | 24.1M | 5.4% | 0.31 | +130.4% | 63.8M |
| 2023 | 361.1M | +21.8% | -74.4M | -20.6% | -1.02 | -100.0% | 34.3M |
| 2022 | 296.5M | — | -36.6M | -12.3% | -0.51 | — | -1M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 50.43 | 52.76 | 21.91 | 24.63 | -50.75% | 41,092,000 | |
| Oct 2026 | 45.66 | 52.39 | 41.22 | 50.01 | +8.62% | 26,014,300 | |
| Sep 2026 | 42.97 | 49.00 | 38.24 | 46.04 | +6.60% | 30,276,500 | |
| Aug 2026 | 46.36 | 47.96 | 40.10 | 43.19 | -6.76% | 27,748,600 | |
| Jul 2026 | 58.99 | 60.82 | 43.52 | 46.32 | -21.13% | 27,330,400 | |
| Jun 2026 | 46.18 | 60.91 | 44.93 | 58.73 | +26.74% | 32,500,200 | |
| May 2026 | 32.97 | 48.35 | 32.13 | 46.34 | +40.77% | 23,644,300 | |
| Apr 2026 | 32.31 | 35.19 | 30.56 | 32.92 | +2.20% | 14,638,400 | |
| Mar 2026 | 35.54 | 36.83 | 29.46 | 32.21 | -11.97% | 23,621,900 | |
| Feb 2026 | 38.11 | 39.89 | 34.17 | 36.59 | -3.91% | 17,393,700 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo (opens in a new tab) SeekingAlpha · 12 Nov 2026 09:57
- Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40 (opens in a new tab) Benzinga · 11 Nov 2026 09:59
- Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 19:11
- Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30 (opens in a new tab) Benzinga · 10 Nov 2026 08:57
- Freedom Capital Markets Maintains Buy on Veracyte, Lowers Price Target to $40 (opens in a new tab) Benzinga · 10 Nov 2026 08:44
- Veracyte, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 09 Nov 2026 18:16
- UBS Maintains Buy on Veracyte, Lowers Price Target to $35 (opens in a new tab) Benzinga · 09 Nov 2026 17:06
- Veracyte (NASDAQ:VCYT): An Undervalued Value Stock With Quality Fundamentals (opens in a new tab) ChartMill · 09 Nov 2026 13:11
- Veracyte (VCYT) Reset Decipher Growth Expectations, Is The Discount Now Too Wide? (opens in a new tab) Simply Wall St. · 07 Nov 2026 07:11
- Why Is Veracyte (VCYT) Drawing Attention For Its Decipher Prostate Test? (opens in a new tab) Simply Wall St. · 06 Nov 2026 21:16
- Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment (opens in a new tab) Zacks · 06 Nov 2026 16:10
- Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 23:54
- Veracyte Crashes Almost 60% On A Seismic Shift. Analysts Decipher What Went Wrong. (opens in a new tab) Investor's Business Daily · 05 Nov 2026 21:22
- Veracyte (VCYT) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 19:46
- Notable Gap Movers on Nov. 5, 2026: AEHL and ZNB Gap Higher; VCYT and MNTN Gap Lower (opens in a new tab) ChartMill · 05 Nov 2026 15:30
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 25.11 USD
- Market cap
- 2.0B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 10.8 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 20.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 14.6 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 15.62× | Fair | 30.56× |
| P/E (forward) | 14.5× | Good | 14.16× |
| Price / book | 1.35× | Good | 3.5× |
| Price / sales | 3.34× | Fair | 3.33× |
| EV / EBITDA | 14.79× | Fair | 11.19× |
| Free cash flow yield | 5.7% | Good | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 74.2% | Good | 54.9% |
| Operating margin | 12% | Fair | 5.8% |
| Net margin | 21.8% | Good | 1.2% |
| Return on equity | 9.4% | Fair | 4.4% |
| Return on assets | 3.7% | Fair | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 20.4% | Good | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.03× | Good | 0.4× |
| Net debt / EBITDA | -3.03× | Good | 1.46× |
| Interest cover | 78,282× | Good | 2.17× |
| Current ratio | 5.56× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow VCYT and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.